Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

Findings illustrate the nature of an Aurora kinase inhibitor that is distinct from others being studied in this class, in its being active in tumor cells that are resistant to traditional antimitotic drugs such as taxanes.